source
- Lilly's retatrutide outperforms Ozempic in phase 3 trial, cutting blood sugar and weight moreEli Lilly tested its triple-G candidate retatrutide against Novo Nordisk's Ozempic (semaglutide) in an open-label phase 3 study involving about 1,300 adults with type 2 diabetes whose glucose was n…
- Astellas commits up to $285M upfront for Audax's preclinical IL-12 program, with potential $1.05B milestonesAstellas Pharma has entered a licensing agreement with Audax Biosciences to gain rights to the latter’s IL-12 immuno‑oncology candidate DAX‑044. Under the deal, Astellas will pay up to $285 millio…